DSIP vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Sleep OptimizationCognitive Enhancement
DSIPGLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- ~13 hours (once-daily dosing)
- Admin Route
- SubQ, IV, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 100–400 mcg
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once nightly
- Once daily
- Key Benefits
- Induces and deepens delta-wave (slow-wave) sleep
- Reduces cortisol and normalizes HPA axis
- Improves sleep quality in insomnia patients
- Anti-stress and anxiolytic effects
- May improve opiate/alcohol withdrawal symptoms
- Analgesic properties through opioid modulation
- Antioxidant and neuroprotective effects
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Generally well tolerated
- Mild grogginess next morning at higher doses
- Rare: hypotension
- Potential for altered dream patterns
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —